Research analysts who have asked questions during Visionary Holdings earnings calls.
SR
Sam Rebotsky
SER Asset Management
4 questions for GV
Also covers: ARTW
Kurt Caramanidis
Carl M. Hennig, Inc.
3 questions for GV
Also covers: SANW
SB
Stephen Branstetter
ABL Investments
3 questions for GV
BL
Bud Leedom
Private Investor
1 question for GV
GG
George Gaspar
Private Investor
1 question for GV
Also covers: BDRL
JD
James Devlin
Henley & Company
1 question for GV
Steve Emerson
Emerson Investment Group
1 question for GV
Also covers: CODA, VENU
S
Steven
ABL Investments
1 question for GV
Also covers: RARE, XEL
Recent press releases and 8-K filings for GV.
Visionary Holdings Inc. Releases FY2025 Annual Report Amid Strategic Shift and Financial Challenges
GV
Earnings
New Projects/Investments
Demand Weakening
- Visionary Holdings Inc. released its final annual report and audited financial statements for fiscal year 2025, reporting total revenue of USD 5.04 million, a 46.2% year-over-year decrease, and a net loss of USD 15.75 million.
- The company is undergoing a strategic transformation from traditional education and real estate towards health management, anti-aging, and medical aesthetics, with these emerging businesses contributing USD 1.06 million or 21.1% of total revenue in FY2025.
- As of March 31, 2025, Visionary Holdings Inc. reported total assets of USD 63.63 million and negative working capital of USD 54.50 million, indicating ongoing liquidity and financing pressures.
- While the final annual report and audited financial statements for FY2025 have been released, the Annual Report on Form 20-F has not yet been filed with the SEC.
Jan 21, 2026, 2:37 AM
Visionary Holdings Inc. Reports Fiscal Year 2025 Annual Results and Strategic Transformation Progress
GV
Earnings
New Projects/Investments
Demand Weakening
- Visionary Holdings Inc. reported total revenue of USD 5.04 million for fiscal year 2025, a 46.2% year-over-year decrease, primarily due to contractions in real estate leasing and education services.
- The company incurred a net loss of USD 15.75 million, attributed to one-time transformation investments, asset impairment charges, and financing costs.
- Visionary Holdings is undergoing a strategic transformation towards health management, anti-aging, and premium medical aesthetics, with these emerging businesses contributing USD 1.06 million (21.1% of total revenue) in FY 2025.
- As of March 31, 2025, Visionary Holdings faced liquidity and financing pressures, including USD 54.50 million in negative working capital and loan defaults, and is pursuing equity financing and debt restructuring.
Jan 13, 2026, 4:38 AM
Visionary Holdings Appoints CEO for Health Technology Business and Establishes New Sales Entity in China
GV
CEO Change
Management Change
New Projects/Investments
- Visionary Holdings Inc. (GV) announced the appointment of Ms. Wenxuan Cai as Chief Executive Officer of its wholly owned subsidiary, Visionary Health Technology Group Limited (GV Hong Kong), effective immediately.
- Concurrently, GV Hong Kong established a new wholly owned subsidiary in Nanjing, China, focused on sales execution and market development.
- These developments signify GV's shift from strategic positioning to active on-the-ground revenue generation in the fields of cellular rejuvenation and aesthetic treatment.
- Ms. Cai's role will involve building and leading regional sales and marketing teams, executing go-to-market strategies, and expanding partnerships to drive sustainable revenue growth.
Dec 30, 2025, 2:30 PM
Visionary Holdings Launches Stem Cell Anti-Aging Product Line
GV
Product Launch
New Projects/Investments
- Visionary Holdings Inc. (GV) has officially launched its medical-grade stem cell anti-aging product line, initially targeting the Chinese mainland and broader Asian markets.
- This launch follows GV's strategic partnership and global technology licensing agreement with Jiangsu Yike Regenerative Medicine Co., Ltd. ("Yike"), integrating Yike's proprietary regenerative technologies into GV's solutions.
- The product portfolio includes a Comprehensive Regenerative Package, Precision Repair Package, and Premium Personalized Program, designed for high-net-worth individuals and clients with specific conditions.
- GV plans to expand its sales and distribution network to include Canada, the United States, and Mexico, in addition to its initial Asian market focus.
- The Company's CEO anticipates this product line will serve as a new driver of profitability in upcoming fiscal years.
Nov 10, 2025, 2:30 PM
Visionary Holdings Inc. Announces Leadership and Governance Restructuring
GV
Board Change
CEO Change
CFO Change
- Visionary Holdings Inc. convened the First Meeting of its Fourth Board of Directors on November 3, 2025, successfully completing key deployments to optimize its governance structure and form a new core team.
- A new Board of Directors was elected, with Mr. William T. Chai as Chairman and Mr. Kealey Donald M as Vice Chairman.
- Four specialized committees were formally established: Audit, Nomination, Compensation, and Investment.
- A new senior management team was appointed, including Mr. Xiyong Hou as Chief Executive Officer (CEO), Mr. Jun Huang as Co-Chief Executive Officer (Co-CEO), Mr. Robert Jay LEES as Chief Operating Officer (COO), and Ms. Xiaolan Liu as Chief Financial Officer (CFO).
Nov 4, 2025, 2:30 PM
Visionary Holdings Inc. 2025 AGM Concludes, Elects New Board, Reappoints Auditor
GV
Board Change
Auditor Change
Proxy Vote Outcomes
- Visionary Holdings Inc. (GV) held its 2025 Annual General Meeting (AGM) on October 31, 2025, where all proposals were approved by an overwhelming majority.
- Nine candidates were elected to the 4th Session of the Board of Directors, and Assentsure PAC was reappointed as the company's auditor for the 2025-2026 fiscal year.
- For the 2024-2025 fiscal year, core businesses accounted for 78% of revenue, new big health projects achieved 100% year-on-year net profit growth, total assets were stable at USD 68,792 thousand, and the asset-liability ratio was 80%.
- The company's strategic focus for the next fiscal year includes improving core businesses, accelerating emerging businesses, and strengthening compliant governance.
Oct 31, 2025, 1:30 PM
Visionary Holdings Launches Stem Cell Joint Venture in Toronto
GV
New Projects/Investments
Product Launch
- Visionary Holdings (GV) has established Visionary Yike Stemcell Technologies Inc., a Canada-based joint venture with Jiangsu Yike Regenerative Medical Technology Co., Ltd.
- The joint venture aims to advance stem cell research, clinical application, and commercialization worldwide, initially focusing on stem cell therapy, immune cell engineering, and AI-supported anti-aging diagnostics and intervention models.
- GV will hold an 85% equity stake in the joint venture, with Yike holding 15%.
- The intended headquarters for the joint venture is GV's property complex at 95–105 Moatfield Drive, Toronto, Ontario, a former IBM headquarters with over 40,000 square meters of space.
- This collaboration seeks to advance the clinical application and commercialization of Yike's breakthrough stem cell technology for Type 1 and Type 2 diabetes.
Oct 22, 2025, 1:30 PM
Visionary Holdings Completes Controlling Stake in Sikang Health Industry Joint Venture
GV
New Projects/Investments
M&A
- Visionary Holdings Inc. (GV) has completed an equity adjustment to obtain a 51% controlling stake in Sikang (Guangzhou) Health Industry Investment Co., Ltd., a joint venture established with Guangzhou Sikang Investment Holding Co., Ltd..
- This transaction, announced on October 17, 2025, marks a key step in Visionary's strategy of "global high-quality industry investment" to promote standardized services and global expansion in the Traditional Chinese Medicine (TCM) health preservation sector.
- The joint venture, initially formed in December 2024, aims to integrate Visionary's capital and global resources with Guangzhou Sikang's operational experience to drive the systematic global layout of TCM health preservation.
- The Joint Venture Platform has already initiated expansion into the Southeast Asian market (Malaysia) as of September 22, 2025, and strengthened domestic channel cooperation on October 7, 2025.
- Visionary's management expects this controlling stake to empower the Joint Venture Platform with compliant capital support, global industrial channels, and resource integration, ultimately building a dual growth curve of "industrial investment + business operation" and creating long-term shareholder value.
Oct 17, 2025, 1:30 PM
GV Secures Global License for Diabetes Stem Cell Technology
GV
New Projects/Investments
Product Launch
Revenue Acceleration/Inflection
- Visionary Holdings (GV), through its wholly owned subsidiary Visionary Holdings (Asia) Limited, has entered into a Global Product and Technology Licensing Agreement with Jiangsu Yike Regenerative Medicine Co., Ltd. (Yike).
- This agreement grants GV worldwide rights to apply Yike's breakthrough stem cell technology, which has demonstrated potential for long-term remission and even complete cure for both Type 1 and Type 2 diabetes.
- The global diabetes treatment market is projected to exceed USD 150 billion in 2024.
- The collaboration features a revenue-sharing arrangement, where GV will benefit from market sales and brand operations, while Yike will generate revenue from technology licensing and clinical R&D.
- GV's CEO, Xiyong Hou, expects this collaboration to significantly contribute to the company's revenue growth in upcoming fiscal years by leveraging its international commercialization network.
Oct 13, 2025, 1:40 PM
Visionary Holdings (Asia) Limited Signs Strategic Cooperation Agreement with Qianxin Bocheng (Jiangsu)
GV
New Projects/Investments
M&A
- Visionary Holdings (Asia) Limited, a wholly owned subsidiary of Visionary Holdings Inc. (Nasdaq: GV), has entered into a strategic cooperation agreement with Qianxin Bocheng (Jiangsu) Technology Development Co., Ltd., an accelerator and industrial park operator.
- The partnership aims to advance the aesthetic treatment industry by combining Qianxin Bocheng's policy support, funding, and industrial park facilities with Visionary Holdings (Asia)'s operational oversight, capital resources, and international experience.
- The cooperation framework covers industrial park cooperation, project incubation, enterprise cultivation and M&A channels, and brand and promotional activities.
- Visionary Holdings (Asia) will have priority to acquire or strategically invest in high-quality projects to integrate them into the GV platform, enhancing industry competitiveness and creating long-term shareholder value.
- The agreement is effective for three years, with renewal subject to mutual agreement.
Sep 24, 2025, 1:30 PM
Quarterly earnings call transcripts for Visionary Holdings.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more